Glenmark launches fixed-dose combination for adults with Type 2 Diabetes in India

The combination contains Remogliflozin, Vildagliptin and Metformin.

Glenmark Pharmaceuticals Limited, a leading pharmaceutical company, announced this morning that it has launched a fixed-dose combination (FDC) of Remogliflozin Etabonate and Vildagliptin with Metformin.  

Remogliflozin Etabonate is a globally researched Sodium-Glucose Co-Transporter Inhibitor (SGLT2i), while Vildagliptin is a Dipeptidyl Peptidase 4 (DPP4) inhibitor. Furthermore, Metformin is used as a first-line medication for the treatment of patients with type 2 diabetes.

This fixed drug combination is indicated for managing Type 2 diabetes. The combination contains Remogliflozin, Vildagliptin and Metformin in the strengths of 100 mg, 50 mg and 500/1000 mg respectively. The FDC is directed to be taken twice daily to improve glycemic control in patients. The company has launched the same under two brand names Remo MV and Remozen MV.

The company is the first one to launch this FDC and intends to improve patient access to SGLT2 inhibitors & DPP4 inhibitors. These inhibitors have proven benefits in the effective management of diabetes with the added advantage of patient compliance.

At 12.49 pm, the share price of Glenmark Pharmaceuticals Limited was trading at Rs 495.8, an increase of 2 per cent over the previous day’s closing price of Rs 486.10 on BSE.